Search results for: Biosimilars
Filter search results
Biosimilar Competition: Lessons from Europe and Prospects for the US
14 March 2014, 12:00am
…biosimilars. At this OHE Lunchtime Seminar, Professor Henry Grabowski presented the results of his recent research on competition in five European countries on Eprex® (epoetin alpha) and Neupogen® (filigrastim) and their biosimilars. He…
What is the impact of Uniform Pricing, Indication-Based Pricing (IBP) and alternative commercial arrangements for new pharmaceuticals in the UK NHS?
19 November 2024
…for generics and biosimilars. Accounting for all these benefits from generic/biosimilar competition in the UP scenario (and for a 100-year time horizon) is unrealistic. The modelling contains naïve assumptions about…
Dr. Sabine Vogler
4 September 2024
…Open, of the Generics and Biosimilars Initiative (GaBI) journal and of the International Advisory Board of the Pharmaceutical Policy and Practice (JOPPP) journal as well as an Associate Editor of…
OHE at ISPOR 2024
5 May 2024, 12:00am
…the Dimensions of Sustainable Global Biosimilars Markets Mireia Jofre-Bonet 06 May 2024 10:30 EDT Poster Session Value Assessment and Reimbursement of Early Treatment for Prevention in Chronic Progressive Diseases: Are…
Breaking the European Deadlock: Part 2 – Transferable Exclusivity Vouchers – Effective Pull Incentive or a Policy Distraction?
4 January 2024
…/use to extend the data protection period of another product in order to ensure predictability for competitor products, including generics and biosimilars. Eligibility criteria linked to obligations for supply of…
Dalia Dawoud
30 June 2023
…journal Value in Health. Dalia is a Director on ISPOR Board of Directors and was past chair of ISPOR Biosimilars Special Interest Group. She is a widely published author in…
The US Inflation Reduction Act: What Do the Experts Think?
25 May 2023
…[13] 유 현, Jang M, Kwon T. EE427: ISPOR – Analyzing the Impact of the Inflation Reduction Act of 2022 on Biosimilars in the United States: A Simulation with Adalimumab…
Projecting Expenditure on Medicines in the NHS
4 January 2013
…in the medicines market, e.g. the appearance of new products and the debut of new generics and biosimilars. The calculations in this study also differ from other estimates by using…
The WHO Technical Report on the Pricing of Cancer Medicines: Missing a Central Role for Value Assessment
8 April 2019
…by volume in high-income countries) are off-patent multi-source generics (and, in the future biosimilars). Advice on the effective procurement of these products is key. Acknowledge that R&D is best incentivised…